Nasus Pharma Ltd. (NYSE: NSRX) announced the initiation of its Phase 2 clinical study for NS002, an investigational intranasal epinephrine ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE